Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count

AIDS

Volumn 21, Issue 13, 2007, Pages 1717-1721

  Phillips, Andrew N ^a   Gazzard, Brian ^a   Gilson, Richard ^a   Easterbrook, Philippa ^a   Johnson, Margaret ^a   Walsh, John ^a   Leen, Clifford ^a   Fisher, Martin ^a   Orkin, Chloe ^a   Anderson, Jane ^a   Pillay, Deenan ^a   Delpech, Valerie ^a   Sabin, Caroline ^a   Schwenk, Achim ^a   Dunn, David ^a   Gompels, Mark ^a   Hill, Teresa ^a   Porter, Kholoud ^a   Babiker, Abdel ^a  

^a NONE

Author keywords

AIDS; CD4 cell count; Cohort study; Death; Rate; Risk; Serious AIDS

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; VIRAL LOAD;

EID: 34547818276     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32827038bf     Document Type: Article

References (18)

1. Lampe FC, Smith CJ, Madge S, Kinloch-de Loes S, Tyrer M, Sabin CA, et al. Success of HIV clinical care according to demographic group among sexually-infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167:684-691.
2. Lampe FC, Gatell J, Staszewski S, Johnson MA, Pradier C, Gill MJ, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy. A multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166:521-528.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the Euro-SIDA study: an observational study. Lancet 2003; 362:22-29.
4. Cooper D, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor in patients with triple class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, February 2007 [abstract 105 aLB].
5. Phillips AN, Gazzard B, Clumeck N, Losso M, Lundgren JD. When should antiretroviral therapy for HIV be started? Br Med J 2007; 334:76-78.
6. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-296.
7. Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, et al. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4(+) cell counts: A EuroSIDA study. J Infect Dis 2006; 194:633-641.
8. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drugnaive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
9. Mocroft A, Youle M, Phillips AN, Halai R, Easterbrook P, Johnson MA, Gazzard B. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Arch Intern Med 1998; 158:491-497.
10. Bogaards JA, Weverling GJ, Geskus RB, Miedema F, Lange JMA, Bossuyt PMM, et al. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis. Antiviral Therapy 2003; 8:43-50.
11. Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19:319-330.
12. Paediatric HIV. Prognostic Markers Group. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20:1289-1294.
13. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186:189-197.
14. The CASCADE Collaboration. Effective therapy has altered the spectrum of causespecific mortality following HIV seroconversion. AIDS 2006; 20:741-749.
15. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus. Arch Intern Med 2006; 166:1632-1641.
16. d'Arminio Monforte A, Abrams D, Pradier C, Weber R, Bonnet F, de Wit S, et al. HIV-induced immunodeficiency and risk of fatal AIDS-defining and non-AIDS-defining malignancies: results from the D:A:D Study. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, February 2007 [abstract 84].
17. Baker J, Peng G, Rapkin J, Abrams D, Silverberg M, Cavert W, et al. HIV related immune suppression after ART predicts risk of nonopportunistic diseases: results from the FIRST study. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, February 2007 [abstract 37].
18. The SMART Study Group. CD4-guided antiretroviral treatment interruption: primary results of the SMART Study. N Engl J Med 2006; 355:2283-2296.